Our products are sold in the United States and select overseas markets. There may also be no clear cause. The most common approach to chronic pain management is pain medication. Side effects, including the potential for addiction are substantial. Increasingly, restrictions are being imposed on access to prescription opioids. DPNCheck is our well-established testing technology for peripheral neuropathies. We believe that growth may rebound in 2021 as the pandemic situation eases. Our more recent products, DPNCheck and Quell, conform to this model. Cumulatively through December 31, 2020, over 198,000 Quell devices have been shipped. DPNCheck is also cleared for marketing in Japan, China and Mexico. He holds both M.D. and Ph.D. degrees. At December 31, 2020, we had an accumulated deficit of $196.9 million. The terms of any financings may not be advantageous to us. The FDA enforces the QSR through periodic inspections. Our issued and filed patents for our wearable therapeutic products are recent. Additionally, we may provoke third parties to assert claims against us. We depend upon third parties for the manufacture of our products or components. If our stock price declines, we may be unable to raise additional capital.